Clinical Trial

Efficacy of 100% Trichloroacetic Acid Vs. Cryotherapy in Xanthelasma Palpebrarum

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 21, 2025 (before its estimated April 7, 2025 completion). Its status may not reflect the trial's current state.
Summary
Xanthelasma palpebrarum (XP) is a common skin condition characterized by yellowish plaques that typically develop around the eyelids. While not harmful, these plaques can be a cosmetic concern for many individuals. Several treatment options exist, but there is no clear consensus on the most effective method. This study aims to compare the effectiveness of two treatment options-100% trichloroacetic acid (TCA) and cryotherapy-in removing xanthelasma palpebrarum. Trichloroacetic acid is a chemical solution that removes the lesions by controlled cauterization, while cryotherapy involves freezing the plaques using liquid nitrogen. A total of 60 patients with xanthelasma will be randomly assigned to receive either 100% TCA or cryotherapy. The success of the treatment will be determined based on whether the plaques flatten and disappear within six weeks. The results of this study will help identify the more effective treatment method, which can be used to improve patient outcomes and minimize recurrence. The study is being conducted at Nishtar Hospital Multan and aims to provide valuable insights for dermatologists in choosing the best treatment for xanthelasma palpebrarum.
Trial Details
NCT Number NCT06839638
Lead Sponsor Nishtar Medical University
Conditions Xanthelasma Palpebrarum
Enrollment 60 participants
Start Date 2024-09-07
Primary Completion 2025-04-07 (estimated)
Study Completion 2025-04-07 (estimated)
Updated on ClinicalTrials.gov 2025-02-21